The CEO received total compensation of approximately $10.7 million, which is within a reasonable range for a healthcare services company of SHC's size (~$4.3B market cap), and the prior Say on Pay vote received over 99% support — well above the 70% threshold that would require demonstrated engagement. The pay mix is heavily performance-oriented: 89% of the CEO's pay is variable or at-risk, including performance stock awards tied to three-year revenue and free cash flow goals, stock price appreciation units that require at least 8% annualized stock price growth to earn anything, and an annual cash bonus tied to Adjusted EBITDA targets. On the pay-for-performance alignment check, SHC's 3-year stock return of -12.7% underperforms XLV (the sector ETF fallback) by 30.6 percentage points, however the company-disclosed peer group median 3-year return is also deeply negative at -24.0%, meaning SHC actually outperforms its own peer group by +11.3 percentage points — the variable pay structure is therefore reasonably aligned with relative shareholder experience, and a clawback policy compliant with SEC and Nasdaq rules is in place.

Non-audit fees (audit-related fees of $20,000 plus tax fees of $521,000 = $541,000) represent approximately 17% of core audit fees of $3,113,000, well below the 50% threshold that would trigger a vote against; EY is a Big 4 firm appropriate for SHC's ~$4.3B market cap; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire, and no material restatements are noted.